Company intelligence / Profile preview

SNOUNDS

Seattle, Washington, United States

Ownership: Private
Development stage: Other

Overview

Sound Pharmaceuticals has reported positive Phase 3 results for its lead candidate SPI-1005 in the treatment of Meniere’s disease. The company is also advancing clinical trials in other indications related to hearing loss and ototoxicity, including cystic fibrosis patients receiving aminoglycoside antibiotics.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on SNOUNDS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNOUNDS.

Explore the full profile